Zoetis
Zoetis is recognized globally as the world’s leading animal health company, with a singular purpose to advance care for animals, backed by over 70 years of innovation in predicting, preventing, detecting, and treating animal illness. Operating in more than 70 countries, Zoetis offers a comprehensive portfolio of vaccines and medicines for both livestock and companion animals. The company is a foundational and dominant force in the Veterinary Monoclonal Antibodies (mAb) market. Zoetis has pioneered the commercial launch of several key mAb products that have significantly improved care for pets with chronic conditions. Its portfolio includes **Lokivetmab** (brand name Cytopoint®), the first USDA- and EMA-approved mAb for canine atopic dermatitis, which targets IL-31 to reduce pruritus. Furthermore, Zoetis offers **Bedinvetmab** (Librela®) for pain associated with canine osteoarthritis and **Frunevetmab** (Solensia®) for feline osteoarthritis pain, establishing them as leaders in non-NSAID pain management. Through continuous investment in R&D and expanded US manufacturing, Zoetis is strengthening its commitment to the next generation of biotherapeutics for companion animals globally.
Latest Market Research Report on Veterinary Monoclonal Antibodies Download PDF Brochure Now
Elanco
Elanco Animal Health Inc. is a global animal health company dedicated to delivering innovative products and services that prevent and treat diseases in farm animals and pets. With approximately 200 brands, Elanco focuses its efforts across Pet Health and Farm Animal Care segments, providing solutions for species ranging from dogs and cats to cattle, poultry, and swine. Monoclonal antibody (mAb) therapies represent a key and growing innovation area for Elanco, positioning it as a significant player in the veterinary biologics market. The company achieved a major milestone in the industry by launching the world’s first **USDA conditionally approved mAb treatment for canine parvovirus**, a significant development for infectious disease management in canines. Elanco is also actively expanding its biologics manufacturing capabilities, supported by investments like the USD 130 million expansion in Kansas, to support its commitment to mAb R&D. By focusing on advancing its mAb pipeline, Elanco aims to bring more antibody-based therapies to market, furthering its mission to improve the health and quality of life for companion and farm animals worldwide.
Merck & Co., Inc. (Merck Animal Health)
Merck & Co., Inc. is a globally recognized healthcare leader, delivering a wide range of innovative solutions, including prescription medications, vaccines, and biologic therapies through its distinct Animal Health division. Merck Animal Health maintains a substantial global footprint, operating in over 140 countries and utilizing an extensive R&D network. The division is a major contributor to the veterinary monoclonal antibody market, specifically focusing on companion animal therapies. Its product portfolio includes the conditionally approved mAb **gilvetmab**, demonstrating its commitment to developing novel biotherapeutic options. To support the increasing demand for advanced biologics, Merck Animal Health has made significant investments, such as the USD 895 million expansion of its manufacturing and R&D facilities in De Soto, Kansas. This expansion is strategically aimed at boosting production capacity and innovation, particularly in biologics and vaccine development, which includes their monoclonal antibody pipeline. Merck’s dedication to its robust R&D network and manufacturing capabilities solidifies its position as one of the top players driving the advancement and accessibility of mAb treatments for animal health.
Boehringer Ingelheim GmbH
Boehringer Ingelheim is a leading global research-driven biopharmaceutical company with a powerful and expansive presence in the Animal Health market, ranking as the second largest animal health business globally. The company operates in more than 150 countries, focusing on Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In the Veterinary Monoclonal Antibodies space, Boehringer Ingelheim is strategically committed to accelerating innovation through partnerships and acquisitions. A key initiative is its collaboration with **Invetx**, a pioneer in protein-based therapeutics for animal health. This partnership leverages Invetx’s cutting-edge discovery platform to develop novel, fully species-specific, and optimized monoclonal antibody biotherapeutics, with Boehringer Ingelheim managing the clinical and regulatory development to bring them to market. The company also signals its focus on the growing animal immune-oncology segment through its acquisition of Saiba Animal Health, expanding its checkpoint-inhibitor pipeline. This strategic approach ensures Boehringer Ingelheim remains at the forefront of introducing breakthrough, highly targeted scientific advancements to meet unmet needs in the rapidly evolving veterinary health market.
Virbac
Virbac is a global veterinary pharmaceutical company dedicated exclusively to animal health, known for its comprehensive and diversified range of products for pets and livestock. The company is actively solidifying its position in the Veterinary Monoclonal Antibodies (mAb) market through strategic partnerships to expand its biologics pipeline. In April 2025, Virbac announced a key licensing agreement with **MabGenesis**. This collaboration grants Virbac the rights to develop and commercialize novel canine therapeutic monoclonal antibodies, leveraging MabGenesis’ advanced phage display and antibody isolation technologies. By focusing on next-generation biologics for companion animals, Virbac aims to address chronic conditions and improve the quality of veterinary care. This investment in mAb R&D and external innovation demonstrates Virbac’s commitment to delivering specialized, high-value therapeutic options to veterinarians and pet owners globally, enhancing its competitiveness in the rapidly growing market for advanced animal biotherapeutics.
Latest Market Research Report on Veterinary Monoclonal Antibodies Download PDF Brochure Now